4 Ways De-Risking Maximizes Compound Value

Most new drugs fail because of ADME/Tox[1]

With early in vitro testing, you can preemptively demonstrate low risk data and **add considerable value to your compound.**

These are facts that industry **must know and leverage** to maximize value. De-risking showcases your compound's performance by …

1 Satisfying Regulatory Requirements

Avoid the **50% risk of IND failure** attributable to inadequate ADME

Provide **required** regulatory information

2 Avoiding Unnecessary Expenses and Approval Delays

- Each day of delay costs $1 million or more, and over 60% of sponsors report delays of 6 months or longer.[2,3] De-risking equates to approx. **$230 million** of added value and that does not include the cost of additional studies and resources!
- **Prevent the losses** of time and other resources caused by clinical failures and additional studies

3 Optimizing Future Development Success

Provide insights into future in vivo study performance

Identify the **best test species** for tox studies

Hone **first in-human** dose selection

Eliminate the need for, or elevate the design of, follow-up clinical studies

4 Ensuring Patient Safety

- Reveal potentially **dangerous drug-drug interactions** before administration to humans

Investing in **high-quality ADME data** helps maximize the value of a compound. Get the return on investment you need with a custom plan from XenoTech.

Visit www.xenotech.com/contact for more information.

XENOTECH
A BioIVT Company

[1] Faqi, A.S., editor. A comprehensive guide to toxicology in nonclinical drug development. Academic Press. Published 2016 November 3.
[2] The University of Texas at Austin. Old Drug Standards Delay New Drug Approvals. Published 2020 June 19.
[3] XenoTech. Industry Survey. Conducted 2021.